Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device Clinical Trials Business Strategies

Bard’s Summer Pipeline Includes Cooling Arctic Blast Products

This article was originally published in The Gray Sheet

  • News

Executive Summary

Executives recently described a series of upcoming product rollouts, including a new temperature management device.

You may also be interested in...



Bard Acquires Neomend Amid Mixed Third Quarter Results

The deal, which has already closed, will “significantly expand” the business opportunities for Bard’s surgical specialties unit, the firm said.

Research In Brief

Trial updates on a drug-coated balloon, a lung cancer genomics assay and deep transcranial magnetic brain stimulation for autism, among clinical data news.

News In Brief

Bard buys Medivance

Table

View full table

Topics

Related Companies

Tags:
Medical Device Clinical Trials Business Strategies
Latest Headlines

ZimVie Wins Investigational Device Exemption For Disc Replacement Device, Plans To Begin Study

Theradaptive Receives $7.4M From DoD, Advances Human Trials With ‘Paint-Like’ Regenerative Therapeutic

Minute Insight: Virtual Incision Draws In Another $30m With Its Table-Top Surgical Robot

Generating And Assessing Evidence To Optimize MDR And IVDR Governance and Innovation

See All
UsernamePublicRestriction

Register

MT031440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By